Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Juli 2020 07:00 ET | Quelle: Cyclacel

Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – ...
03. März 2020 02:00 ET | Quelle: Quanta Dialysis Technologies

Quanta Publishes Study in PLOS ONE: Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+

Quanta Publishes Study in PLOS ONE:Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+ Alcester, Warwickshire, UK, 03 March 2020: Quanta Dialysis Technologies Ltd...
02. August 2018 14:00 ET | Quelle: Summit Therapeutics plc

Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection

Microbiome Damage Caused by Current Treatments May Lead to Disease RecurrenceRidinilazole Reduced Recurrence Rates by 59% versus Standard of Care Vancomycin OXFORD, U.K. and CAMBRIDGE, Mass., Aug. ...
12. Mai 2015 05:08 ET | Quelle: Mesoblast

Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study

NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...